A valid FDA approval under this prediction market must have occurred between January 1, 2025 and December 31, 2029. The approval must be for a novel drug (new molecular entity or new biological product) where the specified protein is explicitly listed as the primary target in the FDA approval documentation. New formulations, biosimilars, and combination products of previously approved drugs do not qualify. Verification will be conducted using the official FDA drugs database (drugs@FDA) as the authoritative source. In cases where a drug has multiple mechanisms of action, the protein must be identified as the primary, not secondary, target.